Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment As Usual in Patients with Schizophrenia

NCT01602029 is registered in ClinicalTrials.gov with Pakistan Institute of Living and Learning as lead sponsor.

NCT NCT01602029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01602029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment As Usual in Patients with Schizophrenia
Lead sponsor
Pakistan Institute of Living and Learning
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
June 30, 2013
Enrollment
303 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis not otherwise specified, schizoaffective disorder, schizophrenia, schizophreniform disorder